drugset / Trial / NCT01859078

A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants

NCT01859078

Phase 1 Completed 28 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to determine the effect of baricitinib on the levels of digoxin in the blood stream and how long it takes the body to remove digoxin. This study will also look at how safe and well-tolerated baricitinib is when given at the same time as digoxin in healthy participants. This study will last approximately 3-4 weeks.

Timeline

Start
2013-05
Primary completion
2013-08
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Baricitinib Small molecule 10 mg Oral
Subject Digoxin Other / unclassified 0.25 mg Oral

Indications

No indication recorded.